The global gene therapy market size accounted for USD 9.26 billion in 2024, grew to USD 11.07 billion in 2025 and is expected to be worth around USD 55.43 billion by 2034, registering a healthy CAGR of 19.60% between 2024 and 2034. The North America gene therapy market size is predicted to increase from USD 5.19 billion in 2024 and is estimated to grow at a fastest CAGR of 19.69% during the forecast year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Gene Therapy Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Gene Therapy Market, by Type, 2024-2034
8.1.1. Gene Silencing
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. Cell Replacement
8.1.2.1. Market Revenue and Forecast (2021-2034)
8.1.3. Gene Augmentation
8.1.3.1. Market Revenue and Forecast (2021-2034)
8.1.4. Other Therapies
8.1.4.1. Market Revenue and Forecast (2021-2034)
9.1. Gene Therapy Market, by Vector, 2024-2034
9.1.1. Viral Vectors
9.1.1.1. Market Revenue and Forecast (2021-2034)
9.1.2. Non-Viral Vectors
9.1.2.1. Market Revenue and Forecast (2021-2034)
10.1. Gene Therapy Market, by Therapeutic Area, 2024-2034
10.1.1. Neurology
10.1.1.1. Market Revenue and Forecast (2021-2034)
10.1.2. Oncology
10.1.2.1. Market Revenue and Forecast (2021-2034)
10.1.3. Hepatology
10.1.3.1. Market Revenue and Forecast (2021-2034)
10.1.4. Other Therapeutic Areas
10.1.4.1. Market Revenue and Forecast (2021-2034)
11.1. Gene Therapy Market, by Delivery Method, 2024-2034
11.1.1. In Vivo
11.1.1.1. Market Revenue and Forecast (2021-2034)
11.1.2. Ex Vivo
11.1.2.1. Market Revenue and Forecast (2021-2034)
12.1. Gene Therapy Market, by Route of Administration, 2024-2034
12.1.1. Intravenous
12.1.1.1. Market Revenue and Forecast (2021-2034)
12.1.2. Other
12.1.2.1. Market Revenue and Forecast (2021-2034)
13.1. North America
13.1.1. Market Revenue and Forecast, by Type (2021-2034)
13.1.2. Market Revenue and Forecast, by Vector (2021-2034)
13.1.3. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
13.1.4. Market Revenue and Forecast, by Delivery Method (2021-2034)
13.1.5. Market Revenue and Forecast, by Route of Administration (2021-2034)
13.1.6. U.S.
13.1.6.1. Market Revenue and Forecast, by Type (2021-2034)
13.1.6.2. Market Revenue and Forecast, by Vector (2021-2034)
13.1.6.3. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
13.1.6.4. Market Revenue and Forecast, by Delivery Method (2021-2034)
13.1.6.5. Market Revenue and Forecast, by Route of Administration (2021-2034)
13.1.7. Rest of North America
13.1.7.1. Market Revenue and Forecast, by Type (2021-2034)
13.1.7.2. Market Revenue and Forecast, by Vector (2021-2034)
13.1.7.3. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
13.1.7.4. Market Revenue and Forecast, by Delivery Method (2021-2034)
13.1.7.5. Market Revenue and Forecast, by Route of Administration (2021-2034)
13.2. Europe
13.2.1. Market Revenue and Forecast, by Type (2021-2034)
13.2.2. Market Revenue and Forecast, by Vector (2021-2034)
13.2.3. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
13.2.4. Market Revenue and Forecast, by Delivery Method (2021-2034)
13.2.5. Market Revenue and Forecast, by Route of Administration (2021-2034)
13.2.6. UK
13.2.6.1. Market Revenue and Forecast, by Type (2021-2034)
13.2.6.2. Market Revenue and Forecast, by Vector (2021-2034)
13.2.6.3. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
13.2.7. Market Revenue and Forecast, by Delivery Method (2021-2034)
13.2.8. Market Revenue and Forecast, by Route of Administration (2021-2034)
13.2.9. Germany
13.2.9.1. Market Revenue and Forecast, by Type (2021-2034)
13.2.9.2. Market Revenue and Forecast, by Vector (2021-2034)
13.2.9.3. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
13.2.10. Market Revenue and Forecast, by Delivery Method (2021-2034)
13.2.11. Market Revenue and Forecast, by Route of Administration (2021-2034)
13.2.12. France
13.2.12.1. Market Revenue and Forecast, by Type (2021-2034)
13.2.12.2. Market Revenue and Forecast, by Vector (2021-2034)
13.2.12.3. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
13.2.12.4. Market Revenue and Forecast, by Delivery Method (2021-2034)
13.2.13. Market Revenue and Forecast, by Route of Administration (2021-2034)
13.2.14. Rest of Europe
13.2.14.1. Market Revenue and Forecast, by Type (2021-2034)
13.2.14.2. Market Revenue and Forecast, by Vector (2021-2034)
13.2.14.3. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
13.2.14.4. Market Revenue and Forecast, by Delivery Method (2021-2034)
13.2.15. Market Revenue and Forecast, by Route of Administration (2021-2034)
13.3. APAC
13.3.1. Market Revenue and Forecast, by Type (2021-2034)
13.3.2. Market Revenue and Forecast, by Vector (2021-2034)
13.3.3. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
13.3.4. Market Revenue and Forecast, by Delivery Method (2021-2034)
13.3.5. Market Revenue and Forecast, by Route of Administration (2021-2034)
13.3.6. India
13.3.6.1. Market Revenue and Forecast, by Type (2021-2034)
13.3.6.2. Market Revenue and Forecast, by Vector (2021-2034)
13.3.6.3. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
13.3.6.4. Market Revenue and Forecast, by Delivery Method (2021-2034)
13.3.7. Market Revenue and Forecast, by Route of Administration (2021-2034)
13.3.8. China
13.3.8.1. Market Revenue and Forecast, by Type (2021-2034)
13.3.8.2. Market Revenue and Forecast, by Vector (2021-2034)
13.3.8.3. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
13.3.8.4. Market Revenue and Forecast, by Delivery Method (2021-2034)
13.3.9. Market Revenue and Forecast, by Route of Administration (2021-2034)
13.3.10. Japan
13.3.10.1. Market Revenue and Forecast, by Type (2021-2034)
13.3.10.2. Market Revenue and Forecast, by Vector (2021-2034)
13.3.10.3. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
13.3.10.4. Market Revenue and Forecast, by Delivery Method (2021-2034)
13.3.10.5. Market Revenue and Forecast, by Route of Administration (2021-2034)
13.3.11. Rest of APAC
13.3.11.1. Market Revenue and Forecast, by Type (2021-2034)
13.3.11.2. Market Revenue and Forecast, by Vector (2021-2034)
13.3.11.3. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
13.3.11.4. Market Revenue and Forecast, by Delivery Method (2021-2034)
13.3.11.5. Market Revenue and Forecast, by Route of Administration (2021-2034)
13.4. MEA
13.4.1. Market Revenue and Forecast, by Type (2021-2034)
13.4.2. Market Revenue and Forecast, by Vector (2021-2034)
13.4.3. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
13.4.4. Market Revenue and Forecast, by Delivery Method (2021-2034)
13.4.5. Market Revenue and Forecast, by Route of Administration (2021-2034)
13.4.6. GCC
13.4.6.1. Market Revenue and Forecast, by Type (2021-2034)
13.4.6.2. Market Revenue and Forecast, by Vector (2021-2034)
13.4.6.3. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
13.4.6.4. Market Revenue and Forecast, by Delivery Method (2021-2034)
13.4.7. Market Revenue and Forecast, by Route of Administration (2021-2034)
13.4.8. North Africa
13.4.8.1. Market Revenue and Forecast, by Type (2021-2034)
13.4.8.2. Market Revenue and Forecast, by Vector (2021-2034)
13.4.8.3. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
13.4.8.4. Market Revenue and Forecast, by Delivery Method (2021-2034)
13.4.9. Market Revenue and Forecast, by Route of Administration (2021-2034)
13.4.10. South Africa
13.4.10.1. Market Revenue and Forecast, by Type (2021-2034)
13.4.10.2. Market Revenue and Forecast, by Vector (2021-2034)
13.4.10.3. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
13.4.10.4. Market Revenue and Forecast, by Delivery Method (2021-2034)
13.4.10.5. Market Revenue and Forecast, by Route of Administration (2021-2034)
13.4.11. Rest of MEA
13.4.11.1. Market Revenue and Forecast, by Type (2021-2034)
13.4.11.2. Market Revenue and Forecast, by Vector (2021-2034)
13.4.11.3. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
13.4.11.4. Market Revenue and Forecast, by Delivery Method (2021-2034)
13.4.11.5. Market Revenue and Forecast, by Route of Administration (2021-2034)
13.5. Latin America
13.5.1. Market Revenue and Forecast, by Type (2021-2034)
13.5.2. Market Revenue and Forecast, by Vector (2021-2034)
13.5.3. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
13.5.4. Market Revenue and Forecast, by Delivery Method (2021-2034)
13.5.5. Market Revenue and Forecast, by Route of Administration (2021-2034)
13.5.6. Brazil
13.5.6.1. Market Revenue and Forecast, by Type (2021-2034)
13.5.6.2. Market Revenue and Forecast, by Vector (2021-2034)
13.5.6.3. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
13.5.6.4. Market Revenue and Forecast, by Delivery Method (2021-2034)
13.5.7. Market Revenue and Forecast, by Route of Administration (2021-2034)
13.5.8. Rest of LATAM
13.5.8.1. Market Revenue and Forecast, by Type (2021-2034)
13.5.8.2. Market Revenue and Forecast, by Vector (2021-2034)
13.5.8.3. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
13.5.8.4. Market Revenue and Forecast, by Delivery Method (2021-2034)
13.5.8.5. Market Revenue and Forecast, by Route of Administration (2021-2034)
14.1. Dimension Therapeutics Inc.
14.1.1. Company Overview
14.1.2. Product Offerings
14.1.3. Financial Performance
14.1.4. Recent Initiatives
14.2. Taxus Cardium Pharmaceuticals Group Inc.
14.2.1. Company Overview
14.2.2. Product Offerings
14.2.3. Financial Performance
14.2.4. Recent Initiatives
14.3. Taxus Cardium Pharmaceuticals Group Inc.
14.3.1. Company Overview
14.3.2. Product Offerings
14.3.3. Financial Performance
14.3.4. Recent Initiatives
14.4. Shanghai Sunway Biotech Co. Ltd
14.4.1. Company Overview
14.4.2. Product Offerings
14.4.3. Financial Performance
14.4.4. Recent Initiatives
14.5. Applied Genetic Technologies Corporation
14.5.1. Company Overview
14.5.2. Product Offerings
14.5.3. Financial Performance
14.5.4. Recent Initiatives
14.6. Applied Genetic Technologies Corporation
14.6.1. Company Overview
14.6.2. Product Offerings
14.6.3. Financial Performance
14.6.4. Recent Initiatives
14.7. American Gene Technologies
14.7.1. Company Overview
14.7.2. Product Offerings
14.7.3. Financial Performance
14.7.4. Recent Initiatives
14.8. BioMarin Pharmaceuticals Inc.
14.8.1. Company Overview
14.8.2. Product Offerings
14.8.3. Financial Performance
14.8.4. Recent Initiatives
14.9. Gensight Biologics S.A.
14.9.1. Company Overview
14.9.2. Product Offerings
14.9.3. Financial Performance
14.9.4. Recent Initiatives
14.10. Sibinono GeneTech Co. Ltd
14.10.1. Company Overview
14.10.2. Product Offerings
14.10.3. Financial Performance
14.10.4. Recent Initiatives
15.1. Primary Research
15.2. Secondary Research
15.3. Assumptions
16.1. About Us
16.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample